Merck KGaA takes its I/O option on F-star Therapeutics; Nephron spends $215M, eyeing spot in Covid-19 vaccine chain
→Merck KGaA has taken an early option on an immuno-oncology program developed at F-star Therapeutics. This is their second option …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
